Want to see STLN full AI Analyst Report?
Starling Oncology Institute (STLN) Stock Price & Analysis
STLN Stock Chart & Stats
- Day’s Range
- $6.19 - $6.37
- 52-Week Range
- $2.32 - $7.13
- Previous Close
- $6.25
- Volume
- N/A
- Average Volume (3M)
- 1.21M
- Market Cap
- $624.89M
- Enterprise Value
- $622.84M
- Total Cash (Recent Filing)
- $41.09M
- Total Debt (Recent Filing)
- $104.48M
- Price to Earnings (P/E)
- ―
- Beta
- 2.11
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
Sustained revenue growth indicates expanding patient, payer and service volumes. Higher scale can improve operating leverage and support the company’s transition toward more predictable, recurring value-based oncology revenue.
Capitated Contract Expansion
Adding capitated lives broadens payer relationships and increases recurring revenue potential. Larger attributed populations also give TOI more opportunity to apply care pathways, manage costs and build a scalable value-based oncology platform.
Improving Cash Flow And Operating Efficiency
The sharp improvement in operating cash flow and lower selling, general and administrative costs suggest better conversion of growth into liquidity. If sustained, these gains can reduce funding needs and improve the economics of expansion.
Bears Say
Negative Equity And Elevated Leverage
Negative equity reflects accumulated losses and leaves limited balance-sheet capacity to absorb setbacks. Significant debt increases refinancing dependence and may constrain investment, contracting flexibility and resilience if growth or profitability falters.
Profitability And Free Cash Flow Not Yet Established
Despite recent adjusted EBITDA and cash-flow improvements, reported earnings power remains unproven and TTM free cash flow is negative. Continued losses could require external funding and make future growth dependent on execution remaining strong.
Medical Loss Ratio And Patient Services Pressure
High and volatile medical loss ratios can compress margins as new capitated members are onboarded. Lower Patient Services profit signals that staffing and care-management costs may run ahead of revenue until contracts mature and pathways improve.
Starling Oncology Institute News
Starling Oncology Institute: Robust Q2, Raised FY26 Outlook and Expanded Delegated Contracts Support Buy Rating and Unchanged $7 Price Target
Matthew Shea, an analyst from Needham, reiterated the Buy rating on Starling Oncology Institute. The associated price target remains the same with $7.00. Matthew Shea has given his Buy rating
STLN FAQ
What was Starling Oncology Institute’s price range in the past 12 months?
What is Starling Oncology Institute’s market cap?
When is Starling Oncology Institute’s upcoming earnings report date?
How were Starling Oncology Institute’s earnings last quarter?
Is Starling Oncology Institute overvalued?
Does Starling Oncology Institute pay dividends?
What is Starling Oncology Institute’s EPS estimate?
How many shares outstanding does Starling Oncology Institute have?
What happened to Starling Oncology Institute’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Starling Oncology Institute?
What is the TipRanks Smart Score and how is it calculated?
Starling Oncology Institute Stock Smart Score
Company Description
Starling Oncology Institute
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Daniel Virnich
- Employees
- 641
- Website
- www.starlingoncology.com
- Address
- 18000 Studebaker Road, Suite 800, Cerritos, CA, 90703, US
Starling Oncology Institute (STLN) Earnings & Revenues
STLN Earnings Call
Earnings Call SentimentPositive
The call highlighted strong revenue growth (34.6% YoY), robust Specialty Pharmacy performance (57.6% revenue growth; 85.1% gross profit growth), improved margins and the company's second profitable quarter as a public company with positive adjusted EBITDA. Cash flow turned positive, free cash flow improved materially, and a refinancing strengthened the balance sheet without dilution. Management also announced meaningful capitated contract wins that add substantial lives and annualized capitation revenue, and they launched a provider portal expected to drive longer-term clinical and commercial benefits. Headwinds include a materially higher MLR (85.5% in Q2 vs 71% prior year), a steep decline in Patient Services gross profit (~57% YoY decline), timing delays that push some launches into Q4 and potential variability in pharmacy margin gains. Overall, the positive top-line, profitability improvement, cash flow progress and balance sheet actions outweigh the near-term operational and margin challenges while scaling capitated lives.
View all STLN earnings summariesSTLN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 4 | 0 | 8 |
